UCLA researchers helped test the first drug approved by the Food and Drug Administration to treat liver cancer in 10 years. They found through clinical trials that the drug, regorafenib, increased overall liver cancer patient survival period from a median of 7.8 months to 10.6 months. Read more...
Photo: The Food and Drug Administration approved the expansion of the use of regorafenib to treat advanced liver cancer April 27 with the help of a UCLA-led research. (Daily Bruin file photo)






